phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»phkinetica-9Research ArticleИССЛЕДОВАНИЯ КЛИНИЧЕСКОЙ ФАРМАКОКИНЕТИКИCLINICAL PHARMACOKINETIC RESEARCHESИсследование фармакокинетики мебеверина в форме капсул с пролонгированным высвобождениемPharmacokinetic study of prolonged release capsules of mebeverineХохловА. Л.KhokhlovA. L.noemail@neicon.ruДжуркоЮ. А.DzhurkoYu. A.noemail@neicon.ruШитовЛ. Н.ShitovL. N.noemail@neicon.ruЯичковИлья ИгоревичYaichkovI. I.Hya_1993_08@mail.ruШитоваА. М.ShitovaA. M.noemail@neicon.ruХозоваЛ. А.KhozovaL. A.noemail@neicon.ruМирошниковА. Е.MiroshnikovA. E.noemail@neicon.ruФГБОУ ВО «Ярославский государственный медицинский университет» МЗ РФ; ООО «Квинта-Аналитика Ярославль»РоссияThe Yaroslavl State Medical University; Quinta-Analytica Yaroslavl LLCRussian FederationООО «Квинта-Аналитика Ярославль»РоссияQuinta-Analytica Yaroslavl LLCRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» МЗ РФРоссияThe Yaroslavl State Medical UniversityRussian Federation201706022017015762Copyright © Хохлов А.Л., Джурко Ю.А., Шитов Л.Н., Яичков И.И., Шитова А.М., Хозова Л.А., Мирошников А.Е., 20172017Хохлов А.Л., Джурко Ю.А., Шитов Л.Н., Яичков И.И., Шитова А.М., Хозова Л.А., Мирошников А.Е.Khokhlov A.L., Dzhurko Y.A., Shitov L.N., Yaichkov I.I., Shitova A.M., Khozova L.A., Miroshnikov A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/9

Было проведено исследование фармакокинетики мебеверина в форме капсул с пролонгированным высвобождением на 24 здоровых добровольцах. Известно, что данное лекарственное вещество полностью метаболизируется на пресистемном этапе. Поэтому измерялись фармакокинетические параметры только его основных метаболитов - мебевериновой кислоты и деметилированной мебевериновой кислоты. Для определения концентрации данных метаболитов в плазме крови разработана биоаналитическая методика с использованием высокоэффективной жидкостной хроматографии с масс-спектрометрическим детектированием.

Pharmacokinetic study of prolonged release capsules of mebeverine was carried out on 24 volunteers. It is known that the drug substance is completely metabolized due to first-pass effect. Therefore, pharmacokinetic parameters of the main metabolites -mebeverine acid and desmethyl mebeverine acid were measured. Bioanalytical method was developed to measurement of concentrations of these metabolites in blood plasma by using HPLC-MS/MS.

мебеверинмебевериновая кислотадеметилированная мебевериновая кислотафармакокинетикаВЭЖХ-МС/МСmebeverinemebeverine aciddesmethyl mebeverine acidpharmacokineticHPLC-MS/MSReferencesBrittain H.G. Analytical Profiles of Drug Substances and Excipients, Vol. 25.California:Academic press, 1998.Brittain H.G. Analytical Profiles of Drug Substances and Excipients, Vol. 25.California:Academic press, 1998.StockisA., Guelen P.J.M., de Vos D. Identification of Mebeverine Acid as the Main Circulating Metabolite of Mebeverine in Man. J Pharm Biomed Anal. 2002; 29: 335-340.StockisA., Guelen P.J.M., de Vos D. Identification of Mebeverine Acid as the Main Circulating Metabolite of Mebeverine in Man. J Pharm Biomed Anal. 2002; 29: 335-340.Winsemius A., Meuwsen I.M., Boon C., van der Laan A., Brekle A., de Vries M. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002; 9 (56): 659-662.Winsemius A., Meuwsen I.M., Boon C., van der Laan A., Brekle A., de Vries M. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002; 9 (56): 659-662.Elliott S., Burgess V. Investigative implications of the Instability and Metabolism of Mebeverine. J Anal Tox. 2006; 30: 91-97.Elliott S., Burgess V. Investigative implications of the Instability and Metabolism of Mebeverine. J Anal Tox. 2006; 30: 91-97.Bergeron M., Bergeron A., Amsterdam P., Furtado M., Garofolo F. Use of polarity switching for the simultaneous bioanalysis of analytes with three orders of magnitude difference in concentration by HPLC-MS/MS. Bioanal. 2013; 5 (15): 1911-1918.Bergeron M., Bergeron A., Amsterdam P., Furtado M., Garofolo F. Use of polarity switching for the simultaneous bioanalysis of analytes with three orders of magnitude difference in concentration by HPLC-MS/MS. Bioanal. 2013; 5 (15): 1911-1918.Khatri C.A., Phanikumar Ch.V., Jayaveera K., Reddy K.Y. Development and Validation of Bioanalytical Method for Simultaneous Quantification of Veratric Acid, Mebeverine Acid and Desmethyl Mebeverine Acid in Human Edta Plasma by Using LC-MS/MS. J Pharm Chem. 2012; 4 (6): 11 - 18.Khatri C.A., Phanikumar Ch.V., Jayaveera K., Reddy K.Y. Development and Validation of Bioanalytical Method for Simultaneous Quantification of Veratric Acid, Mebeverine Acid and Desmethyl Mebeverine Acid in Human Edta Plasma by Using LC-MS/MS. J Pharm Chem. 2012; 4 (6): 11 - 18.Guideline on validation of bioanalytical methods (draft), European Medicines Agency, Committee for medicinal products for human use; 2010.Guideline on validation of bioanalytical methods (draft), European Medicines Agency, Committee for medicinal products for human use; 2010.Guidance for Industry: Bioanalytical method validation. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER), U. S. Government Printing Office, Washington, DC; 2013.Guidance for Industry: Bioanalytical method validation. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER), U. S. Government Printing Office, Washington, DC; 2013.Миронов А.Н., ред. Руководство по экспертизе лекарственных средств. Т. 1. М.: Гриф и К; 2013.Миронов А.Н., ред. Руководство по экспертизе лекарственных средств. Т. 1. М.: Гриф и К; 2013.Food and Drugs Administration Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification SystemRockville, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2015.Food and Drugs Administration Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification SystemRockville, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2015.Guidance on the investigation of bioequivalence,European Medicines Agency, Committee for medicinal products for human use; 2010.Guidance on the investigation of bioequivalence,European Medicines Agency, Committee for medicinal products for human use; 2010.Declaration of Helsinki of the AMM-Ethical Principles for Medical Research in humans, World Medical Assembly, 64th General Assembly; 2013.Declaration of Helsinki of the AMM-Ethical Principles for Medical Research in humans, World Medical Assembly, 64th General Assembly; 2013.Хохлов А.Л., Лилеева Е.Г., Синицина О.А., Спешилова С.А., Демарша С.М., Шитов Л.Н. Проблемы проведения биоаналитической части исследований биоэквивалентности лекарственных препаратов в России. Фармакокинетика Фармакодинамика. 2014; 1: 37-43.Хохлов А.Л., Лилеева Е.Г., Синицина О.А., Спешилова С.А., Демарша С.М., Шитов Л.Н. Проблемы проведения биоаналитической части исследований биоэквивалентности лекарственных препаратов в России. Фармакокинетика Фармакодинамика. 2014; 1: 37-43.

The authors declare that there are no conflicts of interest present.